| Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography C Rousseau, A Devillers, C Sagan, L Ferrer, B Bridji, L Campion, ... Journal of clinical oncology 24 (34), 5366-5372, 2006 | 390 | 2006 |
| Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement F Kraeber-Bodéré, L Campion, C Rousseau, S Bourdin, JF Chatal, ... European journal of nuclear medicine 27 (10), 1487-1493, 2000 | 173 | 2000 |
| Performance comparison of modified ComBat for harmonization of radiomic features for multicenter studies R Da-Ano, I Masson, F Lucia, M Doré, P Robin, J Alfieri, C Rousseau, ... Scientific reports 10 (1), 10248, 2020 | 166 | 2020 |
| Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization … F Kraeber-Bodéré, C Rousseau, C Bodet-Milin, L Ferrer, ... Journal of Nuclear Medicine 47 (2), 247-255, 2006 | 141 | 2006 |
| Brown fat in breast cancer patients: analysis of serial 18F-FDG PET/CT scans C Rousseau, E Bourbouloux, L Campion, N Fleury, B Bridji, JF Chatal, ... European journal of nuclear medicine and molecular imaging 33, 785-791, 2006 | 120 | 2006 |
| Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma … A Oudoux, PY Salaun, C Bournaud, L Campion, C Ansquer, C Rousseau, ... The Journal of Clinical Endocrinology & Metabolism 92 (12), 4590-4597, 2007 | 114 | 2007 |
| Good clinical practice recommendations for the use of PET/CT in oncology PY Salaün, R Abgral, O Malard, S Querellou-Lefranc, G Quere, M Wartski, ... European journal of nuclear medicine and molecular imaging 47, 28-50, 2020 | 113 | 2020 |
| Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma E Mirallié, T Guillan, B Bridji, I Resche, C Rousseau, C Ansquer, ... Surgery 142 (6), 952-958, 2007 | 104 | 2007 |
| Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT T Carlier, T Eugène, C Bodet-Milin, E Garin, C Ansquer, C Rousseau, ... EJNMMI research 3, 1-12, 2013 | 97 | 2013 |
| Radioimmunoconjugates for the treatment of cancer F Kraeber-Bodéré, C Bodet-Milin, C Rousseau, T Eugène, A Pallardy, ... Seminars in oncology 41 (5), 613-622, 2014 | 86 | 2014 |
| Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement PY Salaun, L Campion, C Bournaud, A Faivre-Chauvet, JP Vuillez, ... Journal of Nuclear Medicine 53 (8), 1185-1192, 2012 | 82 | 2012 |
| Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen× anti-hapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in … F Kraeber-Bodéré, A Faivre-Chauvet, L Ferrer, JP Vuillez, PY Brard, ... Clinical cancer research 9 (10), 3973s-3981s, 2003 | 70 | 2003 |
| Nuclear medicine applications for neuroendocrine tumors JF Chatal, MF Le Bodic, F Kraeber-Bodere, C Rousseau, I Resche World journal of surgery 24 (11), 1285-1289, 2000 | 69 | 2000 |
| FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients C Rousseau, A Devillers, M Campone, L Campion, L Ferrer, C Sagan, ... European journal of nuclear medicine and molecular imaging 38, 1029-1036, 2011 | 66 | 2011 |
| A pretargeting system for tumor PET imaging and radioimmunotherapy F Kraeber-Bodéré, C Rousseau, C Bodet-Milin, E Frampas, ... Frontiers in Pharmacology 6, 54, 2015 | 62 | 2015 |
| Tumor immunotargeting using innovative radionuclides F Kraeber-Bodéré, C Rousseau, C Bodet-Milin, C Mathieu, F Guérard, ... International journal of molecular sciences 16 (2), 3932-3954, 2015 | 62 | 2015 |
| FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2) P Vera, S Mezzani-Saillard, A Edet-Sanson, JF Ménard, R Modzelewski, ... European journal of nuclear medicine and molecular imaging 41, 1057-1065, 2014 | 61 | 2014 |
| Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients C Rousseau, L Ferrer, S Supiot, M Bardiès, F Davodeau, ... Tumor Biology 33, 679-688, 2012 | 59 | 2012 |
| Focus on the Controversial Aspects of 64Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging M Colombié, S Gouard, M Frindel, A Vidal, M Chérel, F Kraeber-Bodéré, ... Frontiers in medicine 2, 58, 2015 | 58 | 2015 |
| Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors C Rousseau, AL Ruellan, K Bernardeau, F Kraeber-Bodéré, S Gouard, ... EJNMMI research 1, 1-11, 2011 | 55 | 2011 |
